Sun showed that combination encouraging clinical results, At a speed of nearly twice Cr h D ago with tipifarnib alone in a group of patients for whom chemotherapy Herk Mmliche antileuk mix can not be advanced age, adjusted risk characteristics and biological disease of the poor, or the presence of a significant increase in long-term ??berh h dermatological Komorbidit How it is PHA-739358 Given the observed results from a phase II multicenter, randomized, is planned to compare two cohorts days optimum doses of T  select the maximum t CR with acceptable toxicity T produce the profits. Treatment of minimal residual disease: maintenance chemotherapy in the treatment of long-term CR after cytotoxic therapy is more effective in the context of acute lymphoblastic leukemia chemistry chemistry is not Ngern proven CR mocked in AML patients, especially elderly people or those with low risk .
However, the concept of maintenance therapy after intensive treatment is attractive, even if only as a reference chlich Nnte CR k such treatment or Pr Prevention F FDBK cases, Ngern without severe toxic effects or clonal evolution of leukemia Mie Miezellen l is ridiculously. Elvitegravir It is always possible to change m ver Change AML patients with CR duration too short to be identified, based on clinical and biological properties, which refl ect the St Strength retirement did. The actual product is chlich adults. With one or more risk factors for poor CR median duration of months and years, DFS in these patients provide the so-called state of minimal residual disease a fertile testing ground for new year tze the Verl EXTENSIONS CR and prevent or deter recidivism.
In this regard, it is reasonable to assume that removing k FTI Nnte regrowth of malignant clone, if the residual voltage tumor mass was reduced after cytotoxic chemotherapy in a minimal state. This concept was in AML patients with risk factors fi rst properties tested bad CR relapsed in been enacted. In a phase II study of tipifarnib monotherapy for adults with AML risks such as poor fi CR, mg bid tipifarnib rst days after recovering from consolidation chemotherapy cycles was initiated for maximum. Twenty complete cycles were removed from the study of relapse and prematurely discontinued the drug intolerance. Th H h Hematological toxicity t was rare, but tipifarnib dose reduced myelosuppression. Median DFS was. DFS month for years.
If the RC time for patients U tipifarnib maintenance again with the duration of the CR patients historically Hnlichen U were again the same induction and consolidation therapy, but not tipifarnib in relation to new U seem DFS cushioning for patients with adverse cytogenetic Rer Bek The Geldw tion or two bad risks functions k can be expanded with tipifarnib. This effect of tipifarnib in patients with secondary Rer AML or Rer adverse cytogenetics and is compatible with the facts before tipifarnib activity t t in high-risk MDS patients, in particular Elderly patients with AML, MDS Lich those with unfavorable cytogenetics. On the other hand comparison schl Gt historical Ngern that always engaged DFS maintenance tipifarnib in patients whose only risk factor is age and AML presents no risk of bad biology.